AKAN
Akanda Corp.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · GB
$1.12
−6.67%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.0M | 258.1K | 836.7K | 2.2M | 2.6M |
| Cost of Revenue | 2.3M | 414.1K | 628.3K | 2.0M | 649.9K |
| Gross Profit | (1.3M) | (156.0K) | 208.4K | 111.4K | 3.3M |
| Operating Expenses | |||||
| R&D Expense | — | — | — | — | — |
| SG&A Expense | 10.1M | 4.4M | 4.4M | 5.9M | 19.8M |
| General & Admin Expense | 2.9M | 4.4M | 4.4M | 5.9M | 19.8M |
| Selling & Marketing Expense | 226.8K | — | — | — | — |
| Other Expenses | 636.8K | 433.7K | 141.1K | 4.3M | 2.3M |
| Total Operating Expenses | 10.8M | 4.8M | 4.6M | 10.2M | 22.1M |
| Cost and Expenses | 13.1M | 5.2M | 5.2M | 12.2M | 22.8M |
| Operating Income (EBIT) | (12.1M) | (5.0M) | (4.4M) | (10.1M) | (20.2M) |
| Non-Operating | |||||
| Interest Income | 44.6K | — | 6.5K | 39.00 | 886.00 |
| Interest Expense | 1.8M | 925.1K | 100.1K | 255.7K | 115.3K |
| Net Interest Income | (1.7M) | (925.1K) | (93.6K) | (255.6K) | (114.4K) |
| Other Non-Op Income/Expense | (42.6M) | (42.4M) | 1.1M | (22.2M) | 11.9M |
| Non-Operating Income (excl Interest) | (1.0M) | 41.5M | (1.2M) | 22.0M | (12.1M) |
| EBT (Pre-Tax Income) | (54.7M) | (47.4M) | (3.3M) | (32.3M) | (8.2M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (53.2M) | (45.7M) | (4.1M) | (32.3M) | (11.7M) |
| Earnings from Cont. Ops | (54.7M) | (47.4M) | (3.3M) | (32.3M) | (8.2M) |
| Earnings from Discont. Ops | (237.4K) | 507.6K | (827.6K) | (28.6M) | (3.4M) |
| Bottom Line Net Income | (53.8M) | (45.7M) | (4.1M) | (32.3M) | (11.7M) |
| Per Share | |||||
| Basic EPS | ($757.36) | ($662.22) | ($257.60) | ($2,865,532.00) | ($16,828.00) |
| Diluted EPS | ($757.36) | ($662.22) | ($257.60) | ($2,865,532.00) | ($16,828.00) |
| Revenue Per Share | $1.95 | $3.74 | $50.18 | $196,368.36 | $3,780.20 |
| Shares | |||||
| Basic Shares Outstanding | 525042 | 68941 | 16672 | 11 | 693 |
| Diluted Shares Outstanding | 525042 | 68941 | 16672 | 11 | 693 |
| Profitability Metrics | |||||
| EBITDA | (10.4M) | (46.0M) | (3.0M) | (27.7M) | (4.4M) |
| D&A | 681.9K | 433.7K | 141.1K | 4.3M | 3.8M |
| EBIT | (11.1M) | (46.4M) | (3.2M) | (32.0M) | (8.1M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026